0001610717-24-000027.txt : 20240111 0001610717-24-000027.hdr.sgml : 20240111 20240111195941 ACCESSION NUMBER: 0001610717-24-000027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240109 FILED AS OF DATE: 20240111 DATE AS OF CHANGE: 20240111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krause Kevin Michael CENTRAL INDEX KEY: 0001916925 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 24530361 MAIL ADDRESS: STREET 1: 369 27TH STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 4 1 form4.xml X0508 4 2024-01-09 0001880438 AN2 Therapeutics, Inc. ANTX 0001916925 Krause Kevin Michael C/O AN2 THERAPEUTICS, INC. 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 true Chief Strategy Officer true Common Stock 2024-01-09 4 M 0 2417 0.42 A 4331 D Common Stock 2024-01-09 4 M 0 5000 6.6 A 9331 D Common Stock 2024-01-09 4 S 0 7417 20.1385 D 1914 D Stock Option (right to buy) 0.42 2024-01-09 4 M 0 2417 0 D 2030-01-22 Common Stock 2417 49868 D Stock Option (right to buy) 6.6 2024-01-09 4 M 0 5000 0 D 2031-04-29 Common Stock 5000 26832 D The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date. /s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause 2024-01-11